S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

$198.04
+1.71 (+0.87%)
(As of 03/28/2024 ET)
Today's Range
$196.47
$198.54
50-Day Range
$171.78
$196.33
52-Week Range
$132.24
$243.52
Volume
622,619 shs
Average Volume
986,325 shs
Market Capitalization
$29.13 billion
P/E Ratio
32.73
Dividend Yield
0.97%
Price Target
$198.30

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
0.1% Upside
$198.30 Price Target
Short Interest
Bearish
5.21% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
-0.10mentions of ResMed in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.05 M Sold Last Quarter
Proj. Earnings Growth
9.93%
From $7.45 to $8.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.41 out of 5 stars

Medical Sector

134th out of 938 stocks

Surgical & Medical Instruments Industry

13th out of 95 stocks

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

ResMed's (RMD) "Buy" Rating Reaffirmed at Mizuho
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
ResMed Inc Director Peter Farrell Sells 23,535 Shares
Resmed Inc.
How high could the ResMed share price climb?
RMD Dec 2024 210.000 put
Decoding ResMed Inc (RMD): A Strategic SWOT Insight
Here's Why ResMed (RMD) is a Strong Momentum Stock
ResMed stock jumps after Q2 earnings beat
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/24/2024
Ex-Dividend for 3/14 Dividend
2/07/2024
Dividend Payable
3/14/2024
Today
3/29/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
10,140
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$198.30
High Stock Price Target
$230.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+0.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$897.56 million
Pretax Margin
24.37%

Debt

Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.96 per share
Book Value
$28.11 per share

Miscellaneous

Free Float
145,309,000
Market Cap
$29.13 billion
Optionable
Optionable
Beta
0.65

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed stock has shown a consistent upward trend, with a recent increase of 1.3%.
  • ResMed Inc. operates in the healthcare markets, which are known for their stability and long-term growth potential.
  • The company offers a range of innovative medical devices and cloud-based software applications, catering to a variety of respiratory disorders.
  • ResMed's focus on cloud-based solutions like AirView and myAir demonstrates a commitment to leveraging technology for improved patient outcomes and engagement.
  • With a market capitalization of $27.28 billion, ResMed Inc. is a well-established player in the health care equipment industry.

Cons

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • ResMed Inc. operates in a competitive market with other established players, which could impact its market share and profitability.
  • The company's stock price volatility, with a 1-year high of $243.52 and a 1-year low of $132.24, may pose risks for short-term investors.
  • ResMed's debt-to-equity ratio of 0.27 indicates a moderate level of financial leverage, which could affect its financial stability in economic downturns.
  • The P/E ratio of 30.46 suggests that the stock may be currently overvalued compared to its earnings potential, potentially limiting short-term gains.
  • While ResMed offers innovative solutions, rapid technological advancements in the healthcare industry could pose challenges in maintaining a competitive edge.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

RMD Stock Analysis - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price target for 2024?

10 brokerages have issued 1-year price objectives for ResMed's stock. Their RMD share price targets range from $165.00 to $230.00. On average, they expect the company's stock price to reach $198.30 in the next year. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2024?

ResMed's stock was trading at $172.02 at the beginning of 2024. Since then, RMD stock has increased by 15.1% and is now trading at $198.04.
View the best growth stocks for 2024 here
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings data on Wednesday, January, 24th. The medical equipment provider reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.81 by $0.07. The medical equipment provider earned $1.16 billion during the quarter, compared to analysts' expectations of $1.15 billion. ResMed had a net margin of 19.77% and a trailing twelve-month return on equity of 23.86%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.66 earnings per share.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Wednesday, January 24th. Shareholders of record on Thursday, February 8th will be given a dividend of $0.48 per share on Thursday, March 14th. This represents a $1.92 annualized dividend and a dividend yield of 0.97%. The ex-dividend date of this dividend is Wednesday, February 7th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 0.99%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.44% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (12.06%), Vanguard Group Inc. (12.06%), Northern Trust Corp (0.99%), Norges Bank (0.92%), Legal & General Group Plc (0.76%) and Charles Schwab Investment Management Inc. (0.59%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
This page (NYSE:RMD) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners